SAINT PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals announced today that it has signed an agreement with CTCBIO Inc. of Seoul, South Korea to acquire rights to a novel oral drug delivery technology. Ferring’s success in developing oral formulations for peptide drugs including the world’s first orally active peptide, desmopressin (MINIRIN®) and the fast dissolving lyophilisate (MINIRIN® MELT), is well known. CTCBIO is a growing specialist company that has developed successful manufacturing technologies for more than 30 different drugs, including treatments for dementia and asthma.
Help employers find you! Check out all the jobs and post your resume.
